Despite the frequency with which it occurs, familial hypercholesterolemia often goes undiagnosed, with only 10% of affected patients aware of this genetic disorder.
Statin therapy alone is often insufficient to achieve appropriate lowering of LDL cholesterol levels and additional therapies are needed to complement existing therapies.
Researchers found high rates of dyslipidemia and abnormal HbA1c, including 2 cases of diabetes, after screening for cardiovascular risk factors in middle school students.
There is a high prevalence of discordance in the reduction of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) in response to evolocumab treatment.
Treatment with icosapent ethyl was associated with a substantial reduction in the risk of first, subsequent, and total ischemic events when compared with placebo in statin-treated patients with established cardiovascular (CV) disease or diabetes with other CV risk factors.
